Table 3.

SARS-CoV-2 vaccines in clinical phase III trials and early or limited use.

Vaccine Candidates	Developer	Country	Vaccine Platform	Allocation & Masking	Doses	Timing of doses	Route of Administration	No.
	Wuhan Institute Of Biological Products/Sinopharm	China	Inactivated	Randomized, Double Blind, Parallel Placebo Controlled	2	0, 21days	IM	ChiCTR2000031809 ChiCTR2000034780 ChiCTR2000039000
BBIBP-CorV	Beijing Institute Of Biological Products/Sinopharm	China	Inactivated	Randomized, Triple Blind(Participant, Care Provider, Investigator), Parallel Placebo Controlled	2	0, 21days	IM	ChiCTR2000032459 ChiCTR2000034780 NCT04560881
	Sinovac/Instituto Butantan/Bio Farma	China, Brazil	Inactivated	Randomized, Quadruple Blind(Participant, Care Provider, Investigator, Outcomes Assessor), Parallel Placebo-Controlled	2	0, 14 days	IM	NCT04383574 NCT04352608 NCT04551547 NCT04456595 NCT04582344 669/UN6.KEP/EC/2020
Ad5-nCOV	Cansino Biologics/Beijing Institute Of Biotechnology/Canada’S National Research Council/Petrovax	China, Canada	Non-Replicating Viral Vector	Randomized, Quadruple Blind(Participant, Care Provider, Investigator, Outcomes Assessor), Parallel Placebo-controlled	1(5 × 1010 vp)		IM	ChiCTR2000030906 ChiCTR2000031781 NCT04313127 NCT04341389 NCT04398147 NCT04526990 NCT04540419 NCT04566770 NCT04568811
Sputnik V	Gamaleya Research Institute	Russia	Non-Replicating Viral Vector	Randomized, Double Blind(Participant, Investigator), Parallel Placebo-controlled	2 (0.5 ml/dose+0.5 ml/dose prime-boost)	0, 21days	IM	NCT04437875 NCT04436471 NCT04530396 NCT04564716 NCT04587219
EpiVacCorona	Federal Budgetary Research Institution (Fbri) State Research Center Of Virology And Biotechnology “Vector”	Russia	Protein Subunit	Randomized, Single Blind(Participant), Parallel Placebo-controlleds	2 (0.5 ml)	0, 21days	IM	NCT04527575
Ad26.COV2-S	Janssen Pharmaceutical Companies/Beth Israel Deaconess Medical Center/Emergent Biosolutions/Catalent/Biological E/Grand River Aseptic Manufacturing (Gram)	USA	Non-Replicating Viral Vector	Randomized, Quadruple Blind(Participant, Care Provider, Investigator, Outcomes Assessor), Parallel Placebo-controlled	2 (5 × 1010 vp)	0, 56days	IM	NCT04436276 NCT04505722
AZD 1222	University Of Oxford, Oxford Biomedica, Vaccines Manufacturing And Innovation Centre, Pall Life Sciences, Cobra Biologics, Halixbv, Advent S.R.L., Merck Kgaa, The Serum Institute, Vaccitech, Catalent, Csl, And Astrazeneca/Iqvia	UK	Non-Replicating Viral Vector	Randomized, Quadruple Blind(Participant, Care Provider, Investigator, Outcomes Assessor), Parallel Placebo-controlled	2 (5 × 1010 virus particles (vp))	0, 28days	IM	CTRI/2020/08/027170 EudraCT 2020-001072-15 EudraCT 2020-001228-32 ISRCTN89951424 NCT04324606 NCT04400838 NCT04444674 NCT04516746 NCT04540393 NCT04568031 PACTR202005681895696 PACTR202006922165132
NVX-COV2373	Novavax/Emergent Biosolutions/Praha Vaccines/Biofabri/Fujifilm Diosynth Biotechnologies/Fdb/Serum Institute Of India/Sk Bioscience/Takeda Pharmaceutical Company Limited/Agc Biologics/Polypeptide Group/Endo	India	Protein Subunit	Randomized, Quadruple Blind(Participant, Care Provider, Investigator, Outcomes Assessor), Parallel Placebo-controlled	2 (5 μg SARS-CoV-2 rS + 50 μg Matrix-M1 adjuvant (co-formulated))	0, 21days	IM	NCT04368988 NCT04533399 EudraCT 2020-004123-16 NCT04583995
mRNA 1273	Moderna/Niaid/Lonza/Catalent/Rovi/Medidata/Bioqual	USA	RNA	Randomized, Quadruple Blind(Participant, Care Provider, Investigator, Outcomes Assessor), Parallel Placebo-controlled	2 (100 μg)	0, 28days	IM	NCT04283461 NCT04405076 NCT04470427
BNT162	Biontech/Pfizer/Fosun Pharma/Rentschler Biopharma	Germany, China, USA	RNA	Randomized, Triple Blind(Participant, Care Provider, Investigator), Parallel Placebo Controlled	2 (10, 20, 30 μg BNT162b1 or BNT162b2, or 100μg BNT162b2)	0, 28days	IM	ChiCTR2000034825 EudraCT 2020-001038-36 NCT04368728 NCT04380701 NCT04523571 NCT04537949